Vanguard Group Inc Bio Affinity Technologies, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding BIAF
# of Institutions
15Shares Held
240KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA42.1KShares$91,3090.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny37.5KShares$81,3750.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$60,5100.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$38,1920.0% of portfolio
-
Northern Trust Corp Chicago, IL13.7KShares$29,6460.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $5.92M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...